Technology that enables the fast and sensitive detection of biological and disease specific markers in live tissue is a major need in the diagnostic field. VisEn Medical has developed a breakthrough proprietary […]
Receptor Logic Develops Improved Diagnostic Antibodies
Antibody based diagnostics and therapeutics represent a major medical advance as they respectively identify diseases with high specificity and preclude systemic side effects by recognizing diseased tissue only, yet an important drawback […]
PlexPress Develops Large Scale Genetic Analysis
The streamlining of advanced molecular diagnostics, particularly in genetics, is essential for expanding the use of the most cutting-edge technology throughout the healthcare industry. PlexPress s a biopharmaceutical company that has developed […]
EDP Biotech Detects Early Stage Colon Cancer
Identification and detection of new biomarkers that identify the beginning stages of diseases is critical for achieving successful medical treatment. EDP Biotech Corporation is a medical device company that is developing a […]
MTM Laboratories Can Detect The Earliest Stages of Cervical Cancer
MTM Laboratories has developed a proprietary technological platform that has identified a novel biomarker that serves for the early detection of cervical cancer.
Anavex Receives Approval to Commence Phase I Clinical Trial in Alzheimer’s Disease
Anavex Life Sciences recently announced that its clinical trial application for ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease, has been approved by the German regulatory health authority.
Photocure Develops a Non-surgical Treatment For HPV
A new non-surgical, tissue-preserving therapeutic procedure is being developed to more effectively remove HPV infection and treat precursors of cervical cancer.
Neo Matrix Can Detect Breast Cancer Years Before Tumor Build-Up
Neo Matrix is a medical devices company that has developed a novel diagnostic test to determine breast cancer risk. The company’s test uses breast fluid to analyze the presence of normal, pre-malignant […]
